Advertisement

Topics

Latest "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" News Stories

22:45 EDT 21st March 2019 | BioPortfolio

Here are the most relevant search results for "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" found in our extensive news archives from over 250 global news sources.

More Information about SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated for you to read. Along with our medical data and news we also list SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated Clinical Trials, which are updated daily. BioPortfolio also has a large database of SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated Companies for you to search.

Showing "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" News Articles 1–25 of 29,000+

Thursday 21st March 2019

Global Food Retail Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global Food Retail market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major product...


$12m boost for Australian space sector

The Australian Government has announced $12 million in funding to strengthen the nation’s space sector, consisting of $6 million towards a Mission Control Centre and $6 million to establish a Space Discovery Centre. Both will be based in Adelaide, the home of the Australian Space Agency, and are being built with the support of and in collaboration with the South Australian Government. Minister...

To Abort or Not to Abort–Making Difficult Choices Alone

(Eurekalert) – Almost half of all pregnancies are unplanned. In 2017, 12 733 abortions were carried out in Norway. The number of live births the same year was 56 600. In her doctoral work at the Norwegian University of Science … Read More


Pharmaceutical Collaborations, Rare Diseases Drive the Drugs to Watch in 2019

NewsThe analysis identified seven new drugs forecasted to achieve annual sales of $1 billion or more by 2023.

Turning Point Therapeutics Files Registration Statement for Proposed Initial Public Offering

Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, announced today it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed initial public offering of common stock. The number of shares to be off...

Exploring the Role of Cytoreductive Nephrectomy in RCC

Brian M. Shuch, MD, highlights the complex data with cytoreductive nephrectomy in renal cell carcinoma and offers advice on how to navigate the intricate treatment landscape.

CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)

SUZHOU, China, March 21, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that China's National Medical Products Administration (NMPA) has approved the clinical trial application to begin a Phase 1 trial in China for BLU-667 (CS3009), a highly selective and potent RET inhibitor discovered by CStone's partner Blueprint Medicines. The study is part of Blue...

Study Finds Cancer Drugs Can be Repurposed Beyond Known Uses

The drug sorafenib (Nexavar®) typically used for kidney and liver cancer treatment provided complete remission for breast cancer patient after lab discoveries In an article published today by SAGE Publishing, investigators from The Nagourney Cancer Institute and The Albert Einstein Israelite Hospital in São Paulo, Brazil, announced a new approach to ...

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq and changed Corpora...

Part D Rebates: Policy Tweak Would Retain Manufacturer ‘Contributions’

Peter Bach’s new approach to calculating TrOOP cost in Medicare would prevent big savings to manufacturers from point-of-sale rebates.   

STAT Plus: Biogen halted two trials of the biggest hope for Alzheimer's. Other companies are moving forward with experimental drugs of their own. https://buff.ly/2TULNbR 

STAT Plus: Biogen halted two trials of the biggest hope for Alzheimer's. Other companies are moving forward with experimental drugs of their own. https://buff.ly/2TULNbR 

Novanta to Present at Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019

Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the Needham & Company 18th Annual Healthcare Conference on Tuesday, April 9, 2019, in New York, NY. About Novant...

STAT Plus: After the blowup of the biggest hope for Alzheimer’s, what’s next in the pipeline?

Biogen halted two trials of the biggest hope for Alzheimer's. Other companies are moving forward with experimental drugs of their own.

Dermira nets $122.2mm in FOPO

Dermira Inc. (therapeutics for dermatology indications) netted $122.2mm in a public offering of 9.8mm shares at $13.25. The c...

King Bio Recalls Due To Potential Microbial Contamination Approaches 500

FDA deemed 469 homeopathic remedies manufactured by King Bio – marketed as Dr. King’s: Natural Medicine, Aquaflora, SafeCareRx and Safecare...   

FDA Approves Drug for Daytime Sleepiness in Those with Sleep Apnea, Narcolepsy

The FDA has approved solriamfetol (marketed as Sunosi) to treat excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. The drug is a...

FDA Temporarily Allows Increased Levels of NMBA in Losartan Amid Recalls

The FDA is allowing manufacturers to temporarily sell losartan that has levels of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), which is possibly carcinogenic...

More on SNPs

The first part of this series looked at some approaches to single nucleotide polymorphism (SNP) detection—from brute-force sequencing to the latest solid phase technology, such as DNA chips...

Authority Health Board Names Loretta Bush New President/CEO

The Authority Health Board of Directors has named Loretta V. Bush, MSA, president and CEO of Authority Health, effective May 1, announced Gail Warden, Chairman of the Authority Health Board. Ms. Bush will replace Chris Allen, who has served as president of Authority Health since its inception in 2004, who will retired on April 30. “I am pleased ...

Biogen and Eisai discontinue Phase 3 Alzheimer's trial http://bit.ly/2TQBmH3  #pharma

Biogen and Eisai discontinue Phase 3 Alzheimer's trial http://bit.ly/2TQBmH3  #pharma

Surgical Headlights Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Surgical Headlights report provides an independent information about the Surgical Headlights industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.T...

Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

HANGZHOU, China, March 21, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with pacl...

Physicians Failing To Disclose Supplier, POD Arrangements Fuel Kickback Concerns, Senators Say

US Senate Finance Committee leaders say some physicians may have failed to disclose their physician-ownership interests in entities that offer...   

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint

The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of...   

Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC - FR0013296746), a pharmaceutical company specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces its financial results for the full year ended December 31, 2018. The late-stage French biopharmac...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks